These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 14724989

  • 1. [Heart failure. Can vasopressin antagonists improve the prognosis?].
    MMW Fortschr Med; 2003 Nov 27; 145(48):10. PubMed ID: 14724989
    [No Abstract] [Full Text] [Related]

  • 2. Role of tolvaptan in acute decompensated heart failure.
    Ho JE, Teerlink JR.
    Expert Rev Cardiovasc Ther; 2008 Jun 27; 6(5):601-8. PubMed ID: 18510477
    [Abstract] [Full Text] [Related]

  • 3. Vasopressin antagonism: a future treatment option in heart failure.
    Sanghi P, Uretsky BF, Schwarz ER.
    Eur Heart J; 2005 Mar 27; 26(6):538-43. PubMed ID: 15695526
    [Abstract] [Full Text] [Related]

  • 4. Hyponatremia and outcomes in patients with heart failure.
    Goldsmith SR.
    Heart; 2012 Dec 27; 98(24):1761-2. PubMed ID: 23204533
    [No Abstract] [Full Text] [Related]

  • 5. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
    Schwarz ER, Sanghi P.
    Expert Rev Cardiovasc Ther; 2006 Jan 27; 4(1):17-23. PubMed ID: 16375624
    [Abstract] [Full Text] [Related]

  • 6. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
    Ghali JK, Tam SW.
    J Card Fail; 2010 May 27; 16(5):419-31. PubMed ID: 20447579
    [Abstract] [Full Text] [Related]

  • 7. Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg A.
    Am J Kidney Dis; 2007 Dec 27; 50(6):904-7. PubMed ID: 18037090
    [No Abstract] [Full Text] [Related]

  • 8. Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy?
    Filippatos G, Parissis JT.
    J Card Fail; 2008 Oct 27; 14(8):648-50. PubMed ID: 18926435
    [No Abstract] [Full Text] [Related]

  • 9. [Disorders of body water regulation and the therapy--vasopressin antagonists].
    Ishikawa S, Saito T.
    Nihon Naika Gakkai Zasshi; 1997 Sep 10; 86(9):1654-9. PubMed ID: 9410978
    [No Abstract] [Full Text] [Related]

  • 10. [Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
    Yamamura Y, Sato O, Fujiki H.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():164-8. PubMed ID: 17571379
    [No Abstract] [Full Text] [Related]

  • 11. Tolvaptan (Otsuka).
    Doggrell SA.
    Curr Opin Investig Drugs; 2004 Sep 28; 5(9):977-83. PubMed ID: 15503654
    [Abstract] [Full Text] [Related]

  • 12. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure].
    de Groote P.
    Arch Mal Coeur Vaiss; 2006 Mar 28; 99(3):215-20. PubMed ID: 16618024
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial.
    Pitt B, Gheorghiade M.
    Eur J Heart Fail; 2011 Dec 28; 13(12):1261-3. PubMed ID: 22102625
    [No Abstract] [Full Text] [Related]

  • 16. New heart failure drug shows promise.
    Health News; 2004 Jun 28; 10(6):14. PubMed ID: 15199906
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Conivaptan Yamanouchi.
    Doggrell SA.
    Curr Opin Investig Drugs; 2005 Mar 28; 6(3):317-26. PubMed ID: 15816509
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.